Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 4/2019

01-07-2019 | Metformin | Review Article

The therapeutic potential of metformin in gastric cancer

Published in: Gastric Cancer | Issue 4/2019

Login to get access

Abstract

Metformin is a biguanide molecule used since 1957 to treat type 2 diabetes patients. In addition to its hypoglycemic effects, epidemiological studies have shown that metformin can be associated with a decrease in cancer development risk in diabetic populations. Thus, since 2005 this molecule is largely studied for its antitumoural properties in different types of cancer. The potential antitumoural effect of metformin in gastric cancer has been poorly studied. Here, we detailed the different described mechanisms implicated in the antitumoural effect of metformin in gastric cancer, from the signalling pathways to the functional effects on gastric cancer cell lines and gastric cancer stem cells.
Literature
1.
2.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
3.
Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–60.CrossRefPubMed
4.
Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2016;14:1286–312.CrossRef
5.
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:v38–49.CrossRef
6.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMed
7.
Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.PubMedPubMedCentral
8.
Bailey CJ. Metformin: historical overview. Diabetologia. 2017.
9.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.CrossRefPubMedPubMedCentral
10.
11.
El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223–8.CrossRefPubMed
12.
Madiraju AK, Erion DM, Rahimi Y, Zhang X-M, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542–6.CrossRefPubMedPubMedCentral
13.
Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953–66.CrossRefPubMed
14.
Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355–69.CrossRefPubMedPubMedCentral
15.
Gunton JE, Delhanty PJD, Takahashi S-I, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003;88:1323–32.CrossRefPubMed
16.
Ha J, Guan K-L, Kim J. AMPK and autophagy in glucose/glycogen metabolism. Mol Aspects Med. 2015;46:46–62.CrossRefPubMed
17.
Fischer Y, Thomas J, Rösen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology. 1995;136:412–20.CrossRefPubMed
18.
Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res Phila Pa. 2010;3:1451–61.CrossRef
19.
20.
Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res Phila Pa. 2014;7:867–85.CrossRef
21.
Zhou X-L, Xue W-H, Ding X-F, Li L-F, Dou M-M, Zhang W-J, et al. Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. Oncotarget. 2017;8:55622–31.PubMedPubMedCentral
22.
Lee C, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg. 2016;263:96–102.CrossRefPubMed
23.
Dowling RJO, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31–43.CrossRefPubMed
24.
Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2:896–917.PubMedPubMedCentral
25.
Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle Georget Tex. 2010;9:1057–64.CrossRef
26.
Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013;34:126–35.CrossRefPubMed
27.
Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012;11:549–60.CrossRefPubMed
28.
Chia N-Y, Deng N, Das K, Huang D, Hu L, Zhu Y, et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut. 2015;64:707–19.CrossRefPubMed
29.
Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem. 2003;278:27495–501.CrossRefPubMed
30.
Chang HR, Nam S, Kook M-C, Kim K-T, Liu X, Yao H, et al. HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. 2016;65:19–32.CrossRefPubMed
31.
32.
Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z, et al. Frizzled7 promotes epithelial-to-mesenchymal transition and stemness via activating canonical Wnt/β-catenin pathway in gastric cancer. Int J Biol Sci. 2018;14:280–93.CrossRefPubMedPubMedCentral
33.
Valaee S, Yaghoobi MM, Shamsara M. Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial–mesenchymal transition in a glucose-independent manner. PloS One. 2017;12:e0174486.CrossRefPubMedPubMedCentral
34.
Jun K-H, Lee JE, Kim SH, Jung J-H, Choi H-J, Kim YI, et al. Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncol Rep. 2015;34:2047–53.CrossRefPubMed
35.
Li P, Tong L, Song Y, Sun J, Shi J, Wu Z, et al. Long noncoding RNA H19 participates in metformin-mediated inhibition of gastric cancer cell invasion. J Cell Physiol. 2019;234:4515–4527.CrossRefPubMed
36.
Huang D, He X, Zou J, Guo P, Jiang S, Lv N, et al. Negative regulation of Bmi-1 by AMPK and implication in cancer progression. Oncotarget. 2016;7:6188–200.PubMed
37.
Song Z, Yue W, Wei B, Wang N, Li T, Guan L, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PloS One. 2011;6:e17687.CrossRefPubMedPubMedCentral
38.
Song Z, Wei B, Lu C, Huang X, Li P, Chen L. Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells. Mol Med Rep. 2017;15:1909–15.CrossRefPubMed
39.
Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther. 2015;16:77–87.CrossRefPubMed
40.
Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35:553–62.CrossRefPubMed
41.
42.
Liu JL, Gao W, Kang QM, Zhang XJ, Yang SG. Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis. PloS One. 2013;8:e71930.CrossRefPubMedPubMedCentral
43.
44.
45.
Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao X, et al. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget. 2015;6:12748–62.PubMedPubMedCentral
46.
Villar VH, Nguyen TL, Terés S, Bodineau C, Durán RV. Escaping mTOR inhibition for cancer therapy: tumor suppressor functions of mTOR. Mol Cell Oncol. 2017;4:e1297284.CrossRefPubMedPubMedCentral
47.
Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, et al. Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res. 2015;5:1423–34.PubMedPubMedCentral
48.
Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–11.CrossRefPubMedPubMedCentral
49.
Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012;127:390–7.CrossRefPubMedPubMedCentral
50.
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res Phila Pa. 2012;5:355–64.CrossRef
51.
52.
Courtois S, Durán RV, Giraud J, Sifré E, Izotte J, Mégraud F, et al. Metformin targets gastric cancer stem cells. Eur J Cancer. 2017;84:193–201.CrossRefPubMed
53.
Sekino N, Kano M, Matsumoto Y, Sakata H, Murakami K, Toyozumi T, et al. The antitumor effects of metformin on gastric cancer in vitro and on peritoneal metastasis. Anticancer Res. 2018;38:6263–9.CrossRefPubMed
54.
55.
Chen G, Yu C, Tang Z, Liu S, An F, Zhu J, et al. Metformin suppresses gastric cancer progression through calmodulin-like protein 3 secreted from tumor-associated fibroblasts. Oncol Rep. 2018.
56.
Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015;112:1809–14.CrossRefPubMedPubMedCentral
57.
Courtois S, Bénéjat L, Izotte J, Mégraud F, Varon C, Lehours P, et al. Metformin can inhibit Helicobacter pylori growth. Future Microbiol. 2018;13:1575–1583.CrossRefPubMed
58.
59.
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850–8.CrossRefPubMed
60.
61.
62.
Lesan V, Ghaffari SH, Salaramoli J, Heidari M, Rostami M, Alimoghaddam K, et al. Evaluation of antagonistic effects of metformin with cisplatin in gastric cancer cells. Int J Hematol Oncol Stem Cell Res. 2014;8:12–9.PubMedPubMedCentral
63.
Wu X. Effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS. Pak J Pharm Sci. 2017;30:1833–6.PubMed
64.
Fujita H, Hirose K, Sato M, Fujioka I, Fujita T, Aoki M, et al. Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line. Oncol Lett. 2019;17:2431–40.PubMed
65.
Zhang H-H, Guo X-L. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016;78:13–26.CrossRefPubMed
Metadata
Title
The therapeutic potential of metformin in gastric cancer
Publication date
01-07-2019
Published in
Gastric Cancer / Issue 4/2019
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-019-00952-w

Other articles of this Issue 4/2019

Gastric Cancer 4/2019 Go to the issue

Original Article

Unequal burden of mortality from gastric cancer in Brazil and its regions, 2000–2015

Short Communication

Clinical implications of CTNNA1 germline mutations in asymptomatic carriers

Editorial

Where does signet-ring cell carcinoma come from and where does it go?

Original Article

Prospective feasibility study for single-tracer sentinel node mapping by ICG (indocyanine green) fluorescence and OSNA (one-step nucleic acid amplification) assay in laparoscopic gastric cancer surgery

Original Article

Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method

Case Report

Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits